SIRT3 and prostate carcinoma: They also found that SIRT3 overexpression downregulates the expression of β-catenin in C42B prostate cancer cells, thereby suppressing the Wnt/β-catenin signaling, a pathway that has been shown to inhibit the nuclear localization of FOXO3A and the expression of FOXO3A target genes [170].